University of Connecticut Hematology and Medical Oncology

Topics

• Cancer Immunotherapy and Biomarkers 79
• Parathyroid Disorders and Treatments 62
• Hemoglobinopathies and Related Disorders 54
• Multiple Myeloma Research and Treatments 42
• Cancer-related Molecular Pathways 25
• Chronic Lymphocytic Leukemia Research 25
• Lymphoma Diagnosis and Treatment 24
• Cancer Treatment and Pharmacology 18
• Melanoma and MAPK Pathways 14
• Acute Myeloid Leukemia Research 12
• Cancer Genomics and Diagnostics 12
• Immunotherapy and Immune Responses 12

Most cited

1. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

   Lancet (London, England) · 2024 · 251 citations · Azadeh Namakydoust

2. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.

   The Lancet. Haematology · 2023 · 134 citations · Biree Andemariam

3. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.

   Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022 · 166 citations · Andrew Arnold

4. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.

   Nature medicine · 2021 · 380 citations · Margaret Callahan

5. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 69 citations · Jaykumar Thumar

6. Neoadjuvant relatlimab and nivolumab in resectable melanoma.

   Nature · 2022 · 292 citations ·